Trials / Completed
CompletedNCT04526990
Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above
A Global Multicenter, Randomized, Double-blind, Placebo -Controlled, Adaptive Designed Phase Ⅲ Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of Ad5-nCoV in Adults 18 Years of Age and Older
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 44,247 (actual)
- Sponsor
- CanSino Biologics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This study is a global multicenter, randomized, double-blind, placebo -controlled, adaptive designed phase Ⅲ clinical trial, in order to evaluate the efficacy, safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in adults 18 years old and above.
Detailed description
This is a global phase III clinical trial to evaluate efficacy,safety, immuogenicity of Ad5-nCoV manufactured by Cansino and Beijing Institute of Biotechnology in health adults aged 18 years old and above. The study will be double-blind, placebo-controlled trial with participants randomly allocated 1:1 to placebo and experimental vaccine cohorts. The immunization schedule is one doses intramuscular injections (deltoid).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) | Intramuscular administration |
| BIOLOGICAL | Placebo | Intramuscular administration |
Timeline
- Start date
- 2020-09-15
- Primary completion
- 2021-08-07
- Completion
- 2022-10-21
- First posted
- 2020-08-26
- Last updated
- 2023-06-15
Locations
74 sites across 5 countries: Argentina, Chile, Mexico, Pakistan, Russia
Source: ClinicalTrials.gov record NCT04526990. Inclusion in this directory is not an endorsement.